OCD – Ketamine Ottawa

Obsessive-Compulsive Disorder (OCD)

Rapid relief when traditional OCD treatments fall short

OCD is among the most treatment-resistant psychiatric conditions. Ketamine’s glutamatergic mechanism offers a new avenue for patients who have not achieved adequate relief with SSRIs, clomipramine, or ERP therapy.

Rapid

Symptom onset often within 24–48 hours

Glutamate

Novel mechanism vs. SSRIs

40–60%

OCD patients inadequately treated by SSRIs

Obsessive-compulsive disorder affects approximately 2% of the population and can be profoundly disabling. While exposure and response prevention (ERP) therapy and serotonergic medications (SSRIs, clomipramine) are the evidence-based standards of care, up to 40–60% of patients do not achieve adequate symptom reduction.

For these individuals, the relentless cycle of obsessions and compulsions can dominate every waking hour. The limited treatment options available after first-line failure highlight the urgent need for alternatives.

Ketamine has demonstrated rapid antiobsessional effects in multiple studies — acting through the glutamate system rather than serotonin, which may explain its efficacy in patients who have not responded to serotonergic approaches.

How ketamine helps with obsessive-compulsive disorder (ocd)

The pathophysiology of OCD involves hyperactivity in cortico-striato-thalamo-cortical (CSTC) circuits and dysregulation of glutamatergic signaling. Ketamine’s NMDA receptor blockade rapidly modulates these circuits, reducing the compulsive loop activity that drives OCD symptoms. Studies have demonstrated rapid, significant reductions in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores following ketamine infusion — effects that emerge far faster than any serotonergic treatment.

Book an Appointment

What to expect — your treatment path

OCD-specific evaluation including Y-BOCS scoring and ERP history

Review of prior SSRI trials and augmentation strategies

Tailored infusion course — typically beginning with 4–6 sessions

Y-BOCS reassessment after each session to track response

Coordination with CBT/ERP therapist where applicable

Discussion of maintenance and integration with existing OCD treatment plan

The evidence base

A 2013 double-blind, placebo-controlled crossover study (Rodriguez et al.) demonstrated that a single ketamine infusion produced significant, rapid reductions in OCD symptoms. Subsequent studies have replicated antiobsessional effects, supporting ketamine as a meaningful option for treatment-resistant OCD. Research into repeated infusions and longer-term outcomes is ongoing.

Common questions about ketamine for obsessive-compulsive disorder

Can ketamine be used alongside my current OCD medications?

In most cases, yes. Our physician will review your current SSRI or augmentation regimen and advise on any interactions or adjustments in coordination with your prescribing psychiatrist.

Should I continue ERP therapy during ketamine treatment?

Absolutely. ERP therapy and ketamine are complementary. Ketamine may reduce the subjective distress of obsessions enough to make ERP exposures more tolerable — potentially enhancing the effectiveness of therapy. We encourage maintaining your therapeutic relationship.

How quickly can I expect symptom relief?

Some patients experience a meaningful reduction in obsessive thought intensity within 24–48 hours of the first infusion. The robustness and durability of this response varies by individual and typically strengthens over the course of the initial treatment series.

Ready to explore treatment for obsessive-compulsive disorder?

Our clinical team will review your history and answer your questions — confidentially and with no obligation.